BioSurfaces, a US-based company that deals with advanced nanofiber materials, along with Morphocell Technologies, a Canada-based regenerative medicine company, announced on Friday a collaboration aimed at exploring the potential of BioSurfaces' proprietary Bio-Spun material for therapeutic applications.
With a focus on leveraging Bio-Spun's unique properties to advance innovations in regenerative medicine, the partnership will combine BioSurfaces' expertise in biomaterials with Morphocell's knowledge of cell-based therapies. The companies say that they seek to develop new solutions that address critical healthcare challenges.
The partnership is to concentrate on early-stage research efforts to assess Bio-Spun in various therapeutic applications, with the long-term vision of contributing to the progress of regenerative treatments for patients globally.
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
1Cell.Ai launches OncoIncytes multi-modal cancer diagnostic panel
Viatris seeks Japanese approval for Effexor for generalised anxiety disorder
Kelun-Biotech's SKB518 granted IND clearance by US FDA
WuXi Biologics completes PPQ campaign at 15,000L production line in Hangzhou
SparX to present Phase 1 clinical update during AACR 2025
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
Clario partners with AWS on advancing clinical data analysis with generative AI
Mezzion Pharmaceuticals welcomes dedicated ICD-10 diagnosis codes for Fontan-associated conditions
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025